Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Create SD Holdings Co., Ltd. (3148.T)
Yokohama, JP
Create SD Holdings Co., Ltd., along with its various subsidiaries, conducts business in Japan across the drugstore, pharmacy, and nursing care sectors. Its retail operations provide a broad array of products, including pharmaceuticals, cosmetics, food items, and general household goods. Furthermore, the company manages and operates both residential nursing facilities and day service centers specializing in functional training for the elderly. Complementary services, such as commercial cleaning and administrative support, are also offered. The firm, established in 1998, is headquartered in Yokohama, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.54% | -0.47% | -2.29% | -5.74% | -3.46% | -4.04% | +1.26% | -6.42% | -0.47% | +19.77% | +300.63% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+8.2% ★ Q2'26: +11.3% (vs Q2'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+12.6% Q2'26: +6.3% (vs Q2'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+3.5% Q2'26: +0.0% (vs Q2'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+4.8% Q2'26: +5.2% (vs Q2'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+14.9% ★ Q2'26: +19.6% (vs Q2'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+1.7% Q2'26: 0.0% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.00× ★ Q2'26: 0.04× (vs Q2'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
May 2015 actual |
May 2016 actual |
May 2017 actual |
May 2018 actual |
|---|---|---|---|---|
| Revenue |
213.92B
est: 216.73B (-1.3%)
|
231.89B
est: 236.05B (-1.8%)
|
247.34B
est: 254.60B (-2.9%)
|
268.16B
est: 276.48B (-3.0%)
|
| EBITDA |
13.68B
est: 13.44B (+1.7%)
|
16.85B
est: 14.64B (+15.1%)
|
17.47B
est: 15.79B (+10.6%)
|
17.09B
est: 17.15B (-0.4%)
|
| EBIT |
10.54B
est: 10.91B (-3.5%)
|
13.91B
est: 11.89B (+17.0%)
|
14.51B
est: 12.82B (+13.2%)
|
13.84B
est: 13.92B (-0.6%)
|
| Net Income |
6.56B
est: 6.12B (+7.2%)
|
9.27B
est: 6.94B (+33.7%)
|
10.12B
est: 7.05B (+43.5%)
|
9.54B
est: 7.86B (+21.4%)
|
| SGA |
41.45B
est: 35.50B (+16.7%)
|
44.02B
est: 38.67B (+13.8%)
|
48.06B
est: 41.71B (+15.2%)
|
53.68B
est: 45.29B (+18.5%)
|
| EPS |
101.55
est: 94.79 (+7.1%)
|
146.70
est: 107.38 (+36.6%)
|
160.06
est: 109.20 (+46.6%)
|
150.90
est: 121.63 (+24.1%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-25 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 2/5 | 4/5 |
| 2026-05-15 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-14 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-12 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 4/5 | 4/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-01 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Japan SmallCap Dividend Fund DFJ | 0.13% | 506.7K | 0.58% |
| 2 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.08% | 249.8K | 0.31% |
| 3 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.04% | 247.4K | 0.58% |
| 4 | WisdomTree International SmallCap Dividend Fund DLS | 0.04% | 433.4K | 0.58% |
| 5 | FlexShares Morningstar Developed Markets ex-US Factor Tilt Index Fund TLTD | 0.04% | 259.5K | 0.41% |
| 6 | iShares MSCI Japan Small-Cap ETF SCJ | 0.04% | 97.0K | 0.50% |
| 7 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.03% | 125.5K | 0.48% |
| 8 | Schwab Fundamental International Small Company Index ETF FNDC | 0.03% | 838.3K | 0.39% |
| 9 | Avantis International Small Cap Equity ETF AVDS | 0.02% | 70.6K | 0.30% |
| 10 | Schwab International Small-Cap Equity ETF SCHC | 0.02% | 1.12M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Satoru Ozaki | Corporate Planning Department Manager | — | — |
| Taizo Hirose | President & Representative Director | — | male |
| Tetsuya Yamazaki | Executive Officer & GM of Finance & Accounting Department | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3148.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
